ClinicalTrials.gg
CompletedNCT07930650Updated Nov 12, 2026

Therapy Treatment for CRPS Within a Clinical Setting

An observational study in Chronic Regional Pain Syndrome, sponsored by Walton Centre NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Walton Centre NHS Foundation Trust · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Study summary

Complex regional pain syndrome (CRPS) is a painful and debilitating disorder that usually occurs after limb injury, but can also occur without injury. Persons with CRPS commonly suffer significant levels of disability, loss of function and distress. This in turn can severely compromise a person's quality of life. Guidelines support physiotherapy and occupational therapy treatment for the management of CRPS. It is however not clear from current research as to which particular therapy interventions are most effective. Additionally, the effectiveness of different clinical approaches is poorly reported.

The study aims to establish whether the current therapy treatment offered at the Walton centre for the treatment of CRPS is effective in improving function and activity for people with long-standing complex regional pain syndrome.

Read the detailed description

Complex regional pain syndrome (CRPS) is a painful and debilitating disorder that usually occurs after limb injury, but can also occur without injury. Typical symptoms specific to the affected limb include; painful changes in skin sensitivity, marked swelling, vivid colour changes, pronounced temperature changes, problems with initiation and control of movement and feelings of disconnection with the affected limb. Persons with CRPS commonly suffer significant levels of disability, loss of function and distress. This in turn can severely compromise a person's quality of life. Guidelines support physiotherapy and occupational therapy treatment for the management of CRPS [3]. It is however not clear from current research as to which particular therapy interventions are most effective. Additionally, the effectiveness of different clinical approaches is poorly reported.

Evidence has emerged to support the use of therapy techniques such as graded motor imagery (GMI) as a treatment approach. GMI involves a three stepped approach to retrain the cortex in respect to aspects of motor control. We have published evidence that demonstrated within clinical practice, this treatment approach alone was not effective in terms reducing pain intensity. Since this publication we have continued to integrate aspects of GMI but moved away from using it as a standalone treatment within therapy outpatient clinics.

Within current therapy sessions the overarching treatment principle is to improve sensory and motor processing in order to promote better movement and function. Initial assessment of patients helps therapists to identify relevant treatment approaches that may influence different aspects of the nervous system in respect to this. For example some patients may present with very heightened and painful skin sensations and therefore desensitising techniques that target peripheral nervous system drivers may be of particular relevance. Whereas patients who present with problems recognising their limb or who struggle to initiate active limb movement may benefit from treatment approaches that target retraining the brain in respect to aspects of motor processing. All patients additionally received education regarding pain mechanisms, flare up management and grading and pacing of activities affected by the condition.

The study aims to establish whether the current therapy treatment within the described clinical setting is effective in improving function and activity for people with long-standing complex regional pain syndrome.

Further aims are to:

  • Describe typical therapy treatment delivered within the CRPS therapy clinics for patients with longstanding CRPS.
  • Evaluate impact of treatment in terms of neglect like symptoms, pain and quality of life.
  • Evaluate presenting baseline symptom profiles to help determine what predictors respond and influence response to therapy.
  • To compare changes in outcomes from this patient group with 20 historical patients treated with GMI therapy alone to evaluate potential differences in treatment responses.

This study will analyse already collected data sets and also review patient case notes to obtain further information in respect to therapy treatment, patient demographics and symptom profiles.

02

Conditions studied

  • Chronic Regional Pain Syndrome

Keywords

  • Chronic Regional Pain Syndrome
  • CRPS
  • therapy
03

In context

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 55 are open to participants now.

This study's enrollment of 90 is above the median of 58 across 44 observational studies indexed under Complex Regional Pain Syndromes.

Browse Complex Regional Pain Syndromes studies →

Lead sponsor

Walton Centre NHS Foundation Trust is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with CRPS who have had receipt of treatment at the Walton Centre NHS Foundation Trust

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CRPS
  • Receipt of treatment within the CRPS therapy treatment clinic at the Walton Centre NHS Foundation Trust
  • Adults aged 18 years or above

Exclusion criteria

Exclusion Criteria:

  • Unconfirmed diagnosis of CRPS - i.e. some features of CRPS but patient does not fulfil full diagnostic criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
90 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The Patient-Specific Functional Scale

    This questionnaire can be used to quantify activity limitation and measure meaningful changes in activity.

    Time frame: From baseline (initial CRPS therapy assessment) to completion of CRPS therapy treatment (up to 4 years)

Secondary outcomes

  1. Patient function

    The 'interference with general activity' subscale of the BPI (excluding the walking sub-question in patients affected by CRPS of the upper limb) will be used to assess function

    Time frame: From baseline (initial CRPS therapy assessment) to completion of CRPS therapy treatment (up to 4 years)

  2. Pre and post pain intensity

    Average and worst post-treatment pain intensity compared with before treatment. This is recorded in the BPI questionnaire on a 0-10 NRS where 0 = 'no pain' and 10 = 'pain as bad as you can imagine'

    Time frame: From baseline (initial CRPS therapy assessment) to completion of CRPS therapy treatment (up to 4 years)

  3. Patient Neglect

    Measurement of neglect like symptoms will be taken using the Neglect like symptom questionnaire. This questionnaire is used to confirm the presence of neglect-like symptoms in CRPS patients

    Time frame: From baseline (initial CRPS therapy assessment) to completion of CRPS therapy treatment (up to 4 years)

  4. Patient quality of life

    The EuroQOL-5D-5L measure will be used. Patient perceived global impression of change will be recorded via this questionnaire - this self-report measure reflects a patient's belief about the efficacy of treatment and is widely used in chronic pain clinical trials. Additionally case notes will be reviewed to obtain information regarding condition chronicity, age, gender, medications, details regarding CRPS therapy treatment, number of treatments sessions and discharge outcomes.

    Time frame: From baseline (initial CRPS therapy assessment) to completion of CRPS therapy treatment (up to 4 years)

07

Study locations

1 site
  • The Walton Centre NHS Foundation Trust
    Liverpool, Merseyside L97LJ, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in May 2023, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Nov 12, 2026
StartActual
Nov 30, 2020
Primary completionActual
May 11, 2023
CompletionActual
Apr 30, 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07930650
Lead sponsor
Walton Centre NHS Foundation Trust
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Nov 30, 2020
Primary completion
May 11, 2023
Completion
Apr 30, 2024
Last update
Nov 12, 2026

Study contacts

Louise Haynes
principal investigator · Walton Centre NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion